DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Earlier Triggering in Rec-FSH/GnRH Antagonist Cycles

Information source: Universitair Ziekenhuis Brussel
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: hCG

Intervention: 16mm triggering (Other)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: Universitair Ziekenhuis Brussel

Summary

The effect of altering the timing of hCG administration on the ongoing pregnancy rate in patients stimulated with recombinant-FSH (rec-FSH)/gonadotrophin releasing hormone (GnRH) antagonists for in vitro fertilisation (IVF).

Clinical Details

Official title: Does Earlier Administration Of Human Chorionic Gonadotropin (hCG) Improve The Probability Of Pregnancy In Cycles Stimulated With Rec-FSH AND GnRH Antagonists? A Prospective Randomized Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Ongoing pregnancy rate.

Secondary outcome: number of MII oocytes.

Detailed description: Progesterone elevation has been associated with prolongation of the follicular phase in GnRH antagonists cycles by two days after the commonly used criterion of the presence of at least three follicles of >or= 17 mm has been met. Such an intervention is associated with significantly lower ongoing pregnancy rates in GnRH antagonist cycles, without an apparent deterioration of embryo quality. The adverse effect of P elevation on the day of hCG administration might be explained by the induction of differences at the histological level as well as at the gene expression level between endometrial samples exposed to varying concentrations of progesterone (P). Prolongation of follicular phase by delaying hCG administration for two days is associated with a higher incidence of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles (Kolibianakis et al., 2005). Moreover, Vaerenbergh et al., (2011) demonstrated a distinct difference in endometrial gene expression profile between patients with progesterone serum concentration above and below the threshold of 1. 5 ng/ml on the day of HCG administration. Due to the fact that earlier triggering of final oocyte maturation is expected to result in lower progesterone levels on the day of hCG administration it might be assumed that such an intervention might result in an improved probability of pregnancy by leading to a less deranged and more receptive endometrium. The purpose of this randomized controlled trial is to evaluate whether triggering of final oocyte maturation as soon as ≥ 3 follicles ≥ 16mm are present on ultrasound or one day later affects the probability of pregnancy in patients stimulated with rec-FSH/GnRH- antagonists for IVF.

Eligibility

Minimum age: 18 Years. Maximum age: 39 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:- Age ≤ 39 years

- Body mass index between 18 and 29 kg/m²¬

- Presence of both ovaries

- Basal levels of estradiol (≤ 80 pg/ml) and progesterone (≤ 1. 6ng/ml) on day one of

the cycle

- Treatment with IVF/ICSI

- Embryo transfer on day 3 (1 or 2 embryos)

- Patients can enter in the study only once

Exclusion Criteria:

- Presence of endometriosis stage ≥3(AFS)

- Polycystic ovarian syndrome (Rotterdam criteria)

- Need for preimplantation genetic diagnosis (PGD)

- Azoospermia testicular sperm extraction (TESE)

Locations and Contacts

Additional Information

Starting date: January 2010
Last updated: August 3, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017